
Jack Burnett, CEO, has filed an early warning report after acquiring 4,667,000 common shares of RAMM Pharma Corp from Armando Blankleider for CDN $46,667. This acquisition increases Burnett's stake in the company from 18.47% to 22.38%, totaling 26,720,000 common shares, acquired for investment purposes under a private agreement exemption.
CEO Jack Burnett has materially increased his beneficial ownership in RAMM PHARMA Corp., acquiring an additional 4.667 million common shares at a nominal price of CDN $0.01 per share, for a total consideration of CDN $46,667. This transaction, executed under a private agreement exemption compliant with NI 62-104, elevates Burnett's stake from 18.47% to 22.38% of total outstanding shares, reinforcing his position as a significant insider. While such insider accumulation is often viewed positively, the exceptionally low transaction price and the CEO's stated "investment purposes" warrant careful interpretation, potentially signaling deep perceived undervaluation or specific strategic considerations. Compounding the situation's uncertainty, an external AI-driven stock analysis by InvestingPro, referenced in the context of RAMM's valuation, indicated the company was not among its top-ranked undervalued stocks with substantial upside potential. This independent assessment contributes to the prevailing "moderately negative" sentiment and "uncertain" market tone surrounding the stock, despite the CEO's increased personal investment, and aligns with a low market impact score of 0.25.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.40